

AbCheck adds antibody affinity maturation and developability optimization to its unique Phage and Yeast Display technologies

New technology delivers high quality antibodies through unique technology combinations

Plzen, Czech Republic; November 13, 2012: AbCheck s.r.o., the multi antibody discovery platforms company, announced today the company has licensed a proprietary affinity maturation and optimization technology from Distributed Bio LLC (San Francisco, CA, USA). Under the exclusive, worldwide agreement AbCheck will apply the proprietary computational library design algorithms to address the affinity maturation, therapeutic developability and stability optimization of antibodies in a single one-step process. The addition of this platform to AbCheck's current phage display antibody libraries and Yeast platforms places the company in a unique position to deliver functional, "GMP ready", developable antibodies with significantly increased affinities with minimal mutations from fully human frameworks.

"Not only from a technological standpoint but also from a commercial point of view this partnership between Distributed Bio and AbCheck is a perfect synergy," said Dr. Volker Lang, CEO of AbCheck. "By combining the strength of both technologies we have created a platform that exactly addresses current market needs. Moreover, we can combine this with delivery in very competitive timeframes and maximum flexibility to construct tailor made deals with favorable terms."

"Library design algorithms redefine the full potential of high throughput screening," said Jacob Glanville, Scientific Director of Distributed Bio. "Between affinity maturation, germlining, humanization, stabilization, biochemical liability elimination, immunogenicity minimization, and cross-reactivity modulation, antibody bioengineering has historically been a very time consuming, iterative process. However, decades of global antibody engineering research, combined with the awesome power of next generation sequencing technologies, have given us sophisticated rule sets that dictate the successful construction of biologic medicines. Distributed Bio's library design algorithms encode years of protein bioengineering directly into the library designs. We are delighted to bring this technology forward with AbCheck: their leading edge expertise in antibody engineering and library development make them an ideal partner for introducing this new technology to the market.

About AbCheck

AbCheck s.r.o. focuses on the discovery and/or optimization of human antibodies for partner companies. AbSieve, the combined phage and yeast display platforms, is used to develop antibodies in all antibody formats including full length IgGs as well as customer specific and novel antibody formats. AbAccel, a proprietary algorithm for affinity maturation and optimization, is combined with Phage or Yeast Display and addresses affinity maturation, developability and stability optimization of antibodies in just one step. Antibodies generated by AbCheck's AbSieve and AbAccel platforms have extremely high specificities and affinities, they are "GMP ready" and have improved drugability. Furthermore, the use of Yeast display allows the screening in the final antibody drug format. AbCheck has entered into several partnerships and is recognized for its expertise in antibody discovery throughout the US and Europe.

About Distributed Bio

Distributed Bio is a fully integrated bioinformatics services company specializing in the support of genomic technologies such as NextGen sequencing, antibody informatics and computational bioengineering. By combining unique expertise in computational biology algorithm development with leading technological expertise in data life cycle management, Web2.0 development, high performance, cloud and distributed computing, Distributed Bio licenses, hosts or deploys technologies that massively accelerate biotechnology research. Deployed Distributed Bio solutions have integrated antibody library designs, novel analysis algorithms and platforms, high-performance computing and data infrastructure to produce a complete value chain. The solutions can be hosted on internal client systems, virtually on cloud platforms, or bursting to cloud in hybrid environments. Clients that use Distributed Bio solutions overcome the bioinformatics bottleneck: delivering novel scientific insights faster with little or no infrastructure costs.

For further information please contact:

AbCheck s.r.o.
Dr. Volker Lang
Managing Director

Phone: +420 378 051500
Fax: +420 378 051506
Email: V.Lang@abcheck.eu

Distributed Bio
Giles Day
Managing Director

Phone: +1 415 489 0246
Email: press@distributedbio.com

MC Services AG
Anne Hennecke
Managing Partner

Phone: +49 89 210 228 18
Fax: +49 89 210 228 88
Email: anne.hennecke@mc-services.eu